Edgewise (EWTX) CBO Derakhshan Behrad Receives Option Grant

What Happened
Derakhshan Behrad, Chief Business Officer of Edgewise Therapeutics (EWTX), was granted 100,000 stock options on August 12, 2026. The Form 4 was amended to correct a clerical error: the exercise price for the option grant is $43.56 (the fair market value on the grant date), not $0.00 as originally reported. Because the exercise price equals the fair market value at grant, the options had no immediate intrinsic value reported.

Key Details

• Transaction date: 2026-08-12 (Amended filing submitted 2026-08-17)
• Transaction type: Option grant (derivative award) of 100,000 shares
• Corrected exercise price: $43.56 per share (originally misreported as $0.00)
• Vesting: 1/48th of the option shares vest each month beginning September 12, 2026 (monthly vesting over 4 years), subject to continued service
• Shares owned after transaction: Not specified in the amended Form 4
• Filing status: This is an amended filing correcting the exercise price; no indication in the report that the transaction was an exercise, sale, or part of a 10b5-1 plan

Context
Option grants are a common form of executive compensation. Because the exercise price matches the fair market value on the grant date, the award did not provide immediate, in-the-money value to the insider. The amendment fixes a clerical error and clarifies the economic terms of the grant; it does not indicate any sale or exercise of shares.